Efficacy of Non-invasive Biomarkers in Diagnosing Non-alcoholic Fatty Liver Disease (NAFLD) and Predicting Disease Progression: A Systematic Review
Authors:
- Salma YounasSYSalma Younas
- Fathima Wafa Eranhikkal Jr.FJFathima Wafa Eranhikkal Jr.
Open Access
- 3 February 2025
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 17 (2) , e78421
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, with significant global prevalence and a strong association with metabolic syndrome, obesity, and diabetes. Early diagnosis and prediction of disease progression are critical for effective management. Non-invasive biomarkers have emerged as promising alternatives to liver biopsy, offering safer and more accessible diagnostic and prognostic options. This systematic review evaluates the efficacy of non-invasive biomarkers in diagnosing NAFLD and predicting disease progression, focusing on diagnostic accuracy, clinical utility, and limitations. A systematic review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, including studies published between 2010 and 2024. Databases such as PubMed, Embase, and Scopus were searched using relevant keywords and Boolean operators. Inclusion criteria comprised studies evaluating adults (18+) with NAFLD using non-invasive biomarkers, compared to liver biopsy or other standards, and reporting diagnostic metrics such as sensitivity, specificity, and area under the curve (AUC). Data were extracted systematically, and study quality was assessed using QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies) and the Newcastle-Ottawa Scale. The nine studies include a range of biomarkers such as serum markers (Pro-C3, NIS4), imaging techniques (MRI-PDFF, cT1), and composite scores (cTAG, NFS). Diagnostic accuracy was high, with area under the curve (AUC) values ranging from 0.81 to 0.90 for detecting significant fibrosis and at-risk non-alcoholic steatohepatitis (NASH). Imaging tools such as MRI-PDFF offered superior reproducibility and whole-liver assessments, while composite biomarkers such as NIS4 demonstrated robust sensitivity but moderate specificity. Notable heterogeneity in populations and methodologies was observed. Non-invasive biomarkers show comparable diagnostic performance to liver biopsy while offering significant advantages in safety, scalability, and patient adherence. However, gaps remain, including the need for validation in diverse populations and improved specificity for advanced fibrosis. Integrating non-invasive biomarkers into clinical practice could revolutionize NAFLD management by enabling early diagnosis, guiding treatment, and reducing reliance on invasive methods. Future research should focus on validating these tools across diverse cohorts and developing novel biomarkers to address existing limitations.Keywords
This publication has 31 references indexed in Scilit:
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLDCurrent Obesity Reports, 2024
- 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2022
- Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-AnalysisClinical Gastroenterology and Hepatology, 2022
- Performance of routine risk scores for predicting cirrhosis-related morbidity in the communityJournal of Hepatology, 2022
- ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLDJournal of Hepatology, 2021
- Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver DiseaseArchives of Medical Research, 2021
- NAFLD: Reporting Histologic Findings in Clinical PracticeHepatology, 2020
- Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-AnalysisClinical Gastroenterology and Hepatology, 2020
- The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver diseaseEndocrinology, Diabetes & Metabolism, 2020
- Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real‐World Data From a Large U.S. Claims DatabaseHepatology, 2018